Jupiter Neurosciences (JUNS) Interest Expenses (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Interest Expenses of $62463.0 for Q4 2025, up 211.89% year-over-year from $20027.5 in Q4 2024, and down 99.27% quarter-over-quarter from $8.5 million in Q3 2025.
Jupiter Neurosciences (JUNS) Interest Expenses (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Interest Expenses for 3 consecutive years, with $62463.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses rose 211.89% year-over-year to $62463.0; the TTM figure through Dec 2025 stood at $128682.0 (up 25.22% YoY), while the FY2025 annual figure was $1.8 million, down 98.28% from the prior year.
- Interest Expenses eased to $62463.0 in Q4 2025 per JUNS's latest filing, from $8.5 million in the prior quarter.
- Across five years, Interest Expenses topped out at $8.5 million in Q3 2025 and bottomed at -$55827.0 in Q4 2024.
- Historically, Interest Expenses has averaged $1.4 million across 3 years, with a median of $73183.0 in 2023.
- On a YoY basis, Interest Expenses climbed as much as 4013.81% in 2024 and fell as far as 252.75% in 2024.
- Jupiter Neurosciences' Interest Expenses stood at $36547.0 in 2023, then sank by 252.75% to -$55827.0 in 2024, then soared by 211.89% to $62463.0 in 2025.
- Business Quant data shows JUNS's Interest Expenses at $62463.0 in Q4 2025, $8.5 million in Q3 2025, and $1.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | 90,618.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 62,463.00 |
| Dec 31, 2025 | 62,463.00 |
| Sep 30, 2025 | 8.53 Mn |
| Sep 30, 2025 | 8.53 Mn |
| Jun 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 1.77 Mn |
| Mar 31, 2025 | 405,750.00 |
| Mar 31, 2025 | 405,750.00 |
| Dec 31, 2024 | -55,827.00 |
| Dec 31, 2024 | -55,827.00 |
| Sep 30, 2024 | 3.32 Mn |
| Sep 30, 2024 | 3.32 Mn |
| Jun 30, 2024 | 56,290.00 |
| Jun 30, 2024 | 56,290.00 |
| Mar 31, 2024 | 65,756.00 |
| Mar 31, 2024 | 65,756.00 |
| Dec 31, 2023 | 36,547.00 |
| Dec 31, 2023 | 36,547.00 |
| Sep 30, 2023 | 80,610.00 |
| Sep 30, 2023 | 80,610.00 |